Novartis Ag (NVS) Liabilities from Discontinued Operations (2013 - 2023)

Novartis Ag (NVS) posted Liabilities from Discontinued Operations of 34000000.0 for Q2 2023, up 9.68% sequentially from 31000000.0 in Q4 2019.

Novartis Ag (NVS) Liabilities from Discontinued Operations (2013 - 2023) Analysis & Trends

Novartis Ag has reported Liabilities from Discontinued Operations for 6 years, with the latest figure at 34000000.0 in Q2 2023.

Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 34000000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was 34000000.0 (changed N/A YoY) and the FY2019 annual result came in at 31000000.0, down 39.22% from the prior year.
Liabilities from Discontinued Operations grew to 34000000.0 in Q2 2023 per NVS's latest filing, from 31000000.0 in the prior quarter.
Over five years, Liabilities from Discontinued Operations peaked at 50000000.0 in Q2 2019 and troughed at 24000000.0 in Q3 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	652.20 Bn	631.44 Bn	17.26 Bn
2	AbbVie	469.51 Bn	462.94 Bn	12.70 Bn
3	Merck	376.81 Bn	369.67 Bn	12.21 Bn
4	Novartis Ag	303.04 Bn	295.35 Bn	11.24 Bn
5	Astrazeneca	257.61 Bn	252.71 Bn	12.86 Bn
6	Amgen	237.37 Bn	223.38 Bn	7.24 Bn
7	Gilead Sciences	181.73 Bn	178.55 Bn	6.22 Bn
8	Pfizer	159.66 Bn	147.96 Bn	10.94 Bn
9	Gsk	106.24 Bn	102.07 Bn	8.24 Bn
10	Sanofi	55.07 Bn	47.69 Bn	10.79 Bn

Download Data